黑料网

ISSN: 2161-0460

Journal of Alzheimers Disease & Parkinsonism
黑料网

Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ 黑料网 Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

黑料网 Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Citations : 4334

Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • Academic Keys
  • JournalTOCs
  • China National Knowledge Infrastructure (CNKI)
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • ICMJE
Share This Page

Alzheimer disease research in the 21st century: The shift towards a new paradigm

3rd International Conference on Alzheimers Disease & Dementia

Francesca Pistollato

Physicians Committee for Responsible Medicine, USA

Keynote: J Alzheimers Dis Parkinsonism

DOI:

Abstract
Animal models of Alzheimer disease (AD) have been extensively utilized in the last few decades in an effort to elucidate the pathophysiological mechanisms of this disease and to test novel therapeutic approaches. However, research success has not effectively translated into therapeutic success for human patients. We investigated the reasons for this translational discrepancy. Our analysis revealed that translational failure is due at least in part to the overuse of animal models that cannot accurately recapitulate human AD etiopathogenesis or drug responses and the inadequate use of human-based investigational methods. Here we present the challenges and opportunities in AD research and propose how we can mitigate this translational barrier by employing human-based methods to elucidate disease processes occurring at multiple levels of complexity (from gene expression to protein, cellular, tissue/organ to individual and population level). Novel human-based cellular and computational models are already being applied in toxicology and regulatory testing and the adoption and the widespread implementation of such tools in AD research will undoubtedly facilitate human-relevant data acquisition. Additionally, clinical studies focused on nutritional and lifestyle intervention strategies to reduce and/or prevent early symptoms of AD represent another relevant and important way to elucidate AD pathogenesis and treatment options in a human-based setting. Taken together, it is clear that a paradigm shift towards human-based research is the best way to tackle the ever-increasing prevalence of AD in the 21st century.
Biography

Francesca Pistollato has completed her PhD in Developmental Sciences and Programming Medicine at the University of Padua, Italy. She obtained a Master in Nutrition and Dietetics at the University of Ancona, Italy. She worked as Postdoctoral fellow and research leader at the University of Padua and at the Joint Research Centre (JRC, European Commission). She is currently working as Research Fellow at the Physicians Committee for Responsible Medicine (PCRM), Washington DC. She published several papers and book chapters in reputed scientific journals.

Email: FPistollato@pcrm.org

International Conferences 2024-25
 
Meet Inspiring Speakers and Experts at our 3000+ Global

Conferences by Country

Medical & Clinical Conferences

Conferences By Subject

Top